SignalCorporate

$GSK's Mo-Rez showed a 62% confirmed ORR (28/45) in platinum-resistant ovarian cancer at the 5.8 mg/kg phase III dose, with 12.2-month median DOR and 11.1-month PFS in BEHOLD-1. Grade 3+ TRAEs hit 71%

$GSK's Mo-Rez showed a 62% confirmed ORR (28/45) in platinum-resistant ovarian cancer at the 5.8 mg/kg phase III dose, with 12.2-month median DOR and 11.1-month PFS in BEHOLD-1. Grade 3+ TRAEs hit 71%

GSK

$50.45

-0.38%

What changed

$GSK's Mo-Rez showed a 62% confirmed ORR (28/45) in platinum-resistant ovarian cancer at the 5.8 mg/kg phase III dose, with 12.2-month median DOR and 11.1-month PFS in BEHOLD-1. Grade 3+ TRAEs hit 71%

Why it matters

$GSK's Mo-Rez showed a 62% confirmed ORR (28/45) in platinum-resistant ovarian cancer at the 5.8 mg/kg phase III dose, with 12.2-month median DOR and 11.1-month PFS in BEHOLD-1. Grade 3+ TRAEs hit 71% — impact context not separately stored; see What changed.

Sources